Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03547388
Other study ID # EA2/047/18
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 1, 2018
Est. completion date May 4, 2020

Study information

Verified date May 2020
Source Charite University, Berlin, Germany
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to determine the feasibility and efficacy of moderate weekly whole Body hyperthermia Treatment during radiochemotherapy for pre-irradiated locally or regionally recurrent head and neck squamous cell carcinomas.

The Primary aim of the study is feasibility, defined as 80% of patients completing at least four applications of hyperthermia.

Secondary endpoints include an increase of Tumor Perfusion by the use of hyperthermia, measured by magnetic resonance Imaging during week two of Treatment and reduction of Tumor hypoxia, measured by hypoxia specific Positron emission tomography.


Description:

Previously irradiated patients with loco/ loco-regional recurrent head and neck squamous cell carcinomas usually undergo re-irradiation. However prognosis of these patients is unfavourable, especially for non-human papilloma virus associated cancers. Moderate whole body hyperthermia will be performed by water-filtered IR-A-radiation using a Heckel-HT3000 device.

Preclinical data have indicated that moderate whole body hyperthermia decreases intratumoral interstitial fluid pressure and leads to increased perfusion of the tumor. The study investigates if this holds also true in patients and leads to a marked decrease of tumor hypoxia, measured by 18F-Fluoromisonidazole PET.

The Primary aim of the study is feasibility, defined as 80% of patients completing at least four applications of hyperthermia.

Secondary endpoints include an increase of Tumor Perfusion by the use of hyperthermia, measured by magnetic resonance Imaging during week two of Treatment and reduction of Tumor hypoxia, measured by hypoxia specific Positron emission tomography.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date May 4, 2020
Est. primary completion date May 4, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- patients with unresectable local, regional or loco-regional recurrent non HPV-associated squamous cell head and neck cancer with prior high-dose radiotherapy of the head and neck region

- time interval of 6 months to 5 years after completion of last radiotherapy of the head and neck region

- Completed staging examinations, preferentially 18f-fluorodeoxyglucose (FDG) PET of the whole body

- general health condition according to ECOG status of 0,1 or 2

- age between 18 and 75 years

- written informed consent

Exclusion Criteria:

- HPV associated primary tumor or recurrent tumor

- recurrence more than 5 years after end of previous radiotherapy

- Any medical circumstances impeding the application of radiotherapy, concomitant chemotherapy or whole body hyperthermia

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Moderate whole body hyperthermia using water-filtered IR-A-radiation
four to six applications of whole Body hyperthermia concomitant to radiochemotherapy. Additional measurement of Perfusion and hypoxia by 18F-FMISO hypoxia PET and magnetic resonance Imaging

Locations

Country Name City State
Germany Klinik für Radioonkologie und Strahlentherapie Berlin

Sponsors (2)

Lead Sponsor Collaborator
Charite University, Berlin, Germany Erwin Braun foundation

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary feasibility of whole body hyperthermia as adjunct to radiochemotherapy feasibility is defined as at least 4 cycles of whole body hyperthermia in 80% of patients within 6 weeks of treatment with radiochemotherapy
Secondary Reduction of positron emission tomography (PET) measured hypoxia defined as at least 80% reduction of the tumor to background ratio measured at the end of the second week of treatment compared to pre-treatment 1 year (recruitment) plus additional 2 weeks (evaluation of PET parameter)
Secondary magnetic resonance imaging (MRI) measured perfusion changes measured before treatment and at the end of week 2 1 year (recruitment) plus additional 2 weeks (evaluation of MRI parameter)
Secondary Patient reported quality of life (head and neck cancer specific quality of life) measured by questionnaires according to EORTC (H&N35) and Transformation of absolute values to percentual values. 3 years (i.e. recruitment plus two years of follow-up)
Secondary Patient reported quality of life (general quality of life) measured by questionnaires according to EORTC (C30) and Transformation of absolute values to percentual values. 3 years (i.e. recruitment plus two years of follow-up)
Secondary Local control after 2 years of follow-up From start of re-irradiation. Analysis will be performed by cox regression and log-rank analyses. 3 years (1 year recruitment, 2 years follow-up)
Secondary Loco-regional control after 2 years of follow-up From start of re-irradiation. Analysis will be performed by cox regression and log-rank analyses. 3 years (1 year recruitment, 2 years follow-up)
Secondary Overall survival after 2 years of follow-up From start of re-irradiation. Analysis will be performed by cox regression and log-rank analyses. 3 years (1 year recruitment, 2 years follow-up)
Secondary Freedom from distant metastases after 2 years of follow-up From start of re-irradiation. Analysis will be performed by cox regression and log-rank analyses. 3 years (1 year recruitment, 2 years follow-up)
Secondary Tumor response Response of the irradiated tumor 3 months after end of treatment according to recist criteria 1 year (recruitment) and 3 months (follow-up)
See also
  Status Clinical Trial Phase
Recruiting NCT05980598 - TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Completed NCT02548377 - Remote Ischemic Preconditioning in Head and Neck Cancer Reconstruction - A Randomized Controlled Trial N/A
Active, not recruiting NCT02229656 - Olaparib and Radiotherapy in Head and Neck Cancer Phase 1
Not yet recruiting NCT06289049 - Heavy Strength Training in Head and Neck Cancer Survivors Phase 2
Not yet recruiting NCT06347185 - Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study N/A
Terminated NCT02975739 - Feasibility of Holmium-166 Micro Brachytherapy in Head and Neck Tumors N/A
Recruiting NCT00982436 - Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer Phase 1/Phase 2
Completed NCT01025518 - DAHANCA 25A: Resistance Training and Dietary Supplements as Intervention for Regaining Muscle Mass Following Radiotherapy in Head and Neck Cancer Patients N/A
Active, not recruiting NCT00248235 - Resistance Exercise Training for the Shoulder and Neck Following Surgery for Head and Neck Cancer Phase 2/Phase 3
Terminated NCT00073450 - Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530) Phase 2
Completed NCT00135161 - Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer Phase 1
Not yet recruiting NCT06458517 - Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Mucositis Induced by Radiotherapy, During the Treatment of Head and Neck Cancers N/A
Completed NCT05269342 - Nurse-led Exercise Improves Shoulder Pain, Shoulder Disability, and Quality of Life in Head and Neck Cancer N/A
Recruiting NCT05544136 - A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer Phase 2
Terminated NCT03286972 - PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning
Recruiting NCT04435938 - A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck Phase 2
Recruiting NCT03678649 - A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC Phase 2
Recruiting NCT03975465 - EMST and Swallowing in Long-Term Survivors of HNCA N/A
Completed NCT06446570 - Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma Phase 2
Completed NCT03292250 - Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)] Phase 2